Life-threatening onset of coeliac disease: a case report and literature review

Matteo Guarino,1 Edoardo Gambuti,1 Franco Alfano,1 Andrea Strada,2 Rachele Cicciocioppo 3,3 Lisa Lungaro,1 Giorgio Zoli,1 Umberto Volta,4 Roberto De Giorgio,1 Giacomo Caio 1,5

To cite: Guarino M, Gambuti E, Alfano F, et al. Life-threatening onset of coeliac disease: a case report and literature review. BMJ Open Gastro 2020;e000406. doi:10.1136/bmjgast-2020-000406

Received 19 March 2020
Revised 7 April 2020
Accepted 8 April 2020

ABSTRACT

Background Coeliac disease (CD) results from an immune-mediated reaction to gluten in genetically predisposed individuals. In rare cases CD may occur with acute features deferring the diagnosis and exposing these patients to possible life-threatening complications. Herein we present the case of a young woman with a coeliac crisis, that is, a sudden clinical onset characterised by severe electrolyte imbalance due to an unknown (previously unrecognised) CD.

Methods This is a case report and literature review revealing that coeliac crisis is under-reported, with a total of 48 adult cases so far published. The diagnosis in our case was established by histopathological analysis of multiple duodenal biopsies. The patient’s serum was tested by enzyme-linked immunoassay to detect antitransglutaminase IgA antibodies.

Results In contrast to cases reported in the literature, with male gender predominance and a mean age of 50±17 years, our patient was a young female case of coeliac crisis. However, like in our patient, a higher incidence of coeliac crisis was associated with the human leucocyte antigen (HLA)-DQ2 haplotype, versus HLA-DQ8, and a severe (Marsh-Oberhuber 3c) duodenal mucosa atrophy. Notably, there is no clear correlation between the antitransglutaminase 2 IgA antibody titre and coeliac crisis onset/severity, as confirmed by our case report.

Conclusions The present case highlights that CD may manifest quite abruptly with a severe malabsorption syndrome, that is, electrolyte abnormalities and hypoproteinaemia. Our case should alert physicians, in particular those in the emergency setting, that even a typically chronic disorder, such as CD, may show life-threatening complications requiring urgent management.

INTRODUCTION

Coeliac disease (CD) is a multisystemic, immune-mediated illness evoked by gluten ingestion in genetically susceptible individuals. The main target organ of the autoimmune reaction against the enzyme tissue transglutaminase (TG2) is the small bowel, where the gluten-related inflammatory cascade causes a progressive mucosal damage leading to severe villous atrophy. From a clinical standpoint, CD is a multifaceted chronic condition displaying a broad spectrum of intestinal (ranging from mild irritable bowel syndrome-like to severe malabsorption symptoms) and extraintestinal manifestations targeting several tissues and organs (eg, skin, endocrine/exocrine glands, nervous system, joint/muscles). As a result, CD remains a challenging condition to be diagnosed, thus causing a significant delay in establishing the appropriate therapy and increasing related morbidity.

A potentially life-threatening and neglected clinical manifestation of CD is the so-called ‘coeliac crisis’, characterised by acute, massive watery diarrhoea, severe dehydration and metabolic disturbances, leading to neuromuscular weakness, tetanic seizures, cardiac arrhythmias and even sudden death in extreme cases. In most cases, coeliac crisis develops due to voluntary or inadvertent gluten ingestion in patients with or without an established diagnosis of CD. Only rarely a coeliac crisis heralds the clinical onset of CD, requiring hospitalisation and rapid therapeutic management due to possible occurrence of severe complications with high morbidity and mortality.

Herein we describe the case of a patient admitted to our emergency department for a severe life-threatening coeliac crisis as the first manifestation of a previously unknown CD.

CASE REPORT

A 34-year-old woman was admitted to the emergency unit complaining of limb...
Figure 1  Representative duodenal endoscopic picture showing decreased mucosal folds carrying a scalloping profile, together with a mosaic pattern and an increased vascular network (arrow), all suggestive of villous atrophy.

numbness and watery diarrhoea (8–10 bowel movements/day) which started 2 weeks earlier. The patient reported a weight loss of about 10 kg in the last 2 months in the absence of hyporexia. Her clinical history unravelled microcytic anaemia treated with oral iron replacement. Physical examination showed severe weakness of the limbs with a bilaterally positive Trousseau’s sign without cardiorespiratory abnormalities. Vital parameters were within the normal range. The abdomen was flat, without tenderness, while auscultation disclosed increased intestinal sounds. Her ECG showed a sinus rhythm with type 1 atrioventricular block, flat T waves associated with U waves and an elongated QTc interval (570 ms). Laboratory tests revealed severe electrolyte imbalance, with hyponatraemia (133 mmol/L), hypokalaemia (1.6 mmol/L), hypocalcaemia (ionised calcium of 0.9 mmol/L), hypophosphataemia (1.6 mg/dL) and hypomagnesaemia (1.4 mmol/L). Furthermore, the patient had hypochromic microcytic anaemia (haemoglobin of 85 g/L, with a mean cell volume of 68 fL and a mean cell haemoglobin of 20.6 pg), normal platelet count (297 x 10⁹/L), iron (serum iron 18 pg/dL; ferritin 2 ng/mL) and folate deficiency (2 ng/mL), as well as hypoproteinaemia and hypoalbuminaemia (total serum protein 4.4 g/dL; albumin 2.6 g/dL). Due to severe electrolyte imbalance, a conspicuous electrolyte replacement was rapidly administered, leading to a slight improvement in electrocardiographic abnormalities. The patient was then admitted to the internal medicine ward for adequate investigation and treatment. During the hospitalisation, the common causes of infectious diarrhoea were excluded by stool cultures, and the faecal occult blood test resulted negative. Both ultrasound and abdominal X-ray examinations were unremarkable. Liver function tests revealed a slight increase of transaminases, with alanine transaminase and aspartate transaminase values of 47 U/L and 60 U/L (n.v. 5-35 for both parameters), respectively. Based on the lack of fever, normal C reactive protein and the presence of non-bloody, watery diarrhoea, the patient was further evaluated with an upper endoscopy. The examination revealed stigmata of villous atrophy at the duodenal level (figure 1), where biopsies were taken from the bulb and the second portion. Histopathological analysis showed the presence of a severe villous atrophy (Marsh-Oberhüber grade 3c) (figure 2) without any evidence of aberrant intraepithelial lymphocytes. Based on the histopathological result, we used enzyme-linked immunosorbent assay to test IgA anti-TG2, which turned to be positive at low titre (23 U/mL, n.v. <10 U/mL). This result was associated with the positivity of IgA antiendomysial antibodies (1:80) revealed by indirect immunofluorescence. The genetic test showed human leucocyte antigen (HLA)-DQ2 positivity. Therefore, a firm diagnosis of CD was established and the patient started a gluten-free diet (GFD). Due to rapid improvement after gluten withdrawal, a course with steroid treatment was deemed not necessary. Since diarrhoea and paraesthesia showed significant improvement with complete regression in about a week, the patient was discharged in good health.

DISCUSSION AND REVIEW OF THE LITERATURE

In the vast majority of cases, the natural history of CD is characterised by chronic evolution without acute exacerbations. Conversely, coeliac crisis is burdened by severe acute symptoms such as abdominal pain and distension, massive diarrhoea and weight loss, causing a life-threatening malabsorption syndrome. In most cases, gluten is introduced inadvertently, whereas in some patients with poor compliance to GFD a voluntary
Table 1  Synopsis highlighting the main features of adult cases (n=48) with coeliac crisis published so far

| Reference          | Age  | Sex | Weight loss | Favorable evolution with GFD | Biopsy (Marsh grade) | EMA | TG2 (UI/mL) | HLA | Hb (g/L) | PLT (x10^9/L) | INR | Hypo-proteinemia | Electrolyte Abnormalities | LOS (days) | Death |
|--------------------|------|-----|-------------|------------------------------|----------------------|-----|-------------|-----|----------|---------------|-----|----------------|---------------------------|------------|-------|
| Ozaslan et al^8    | 75   | M   | Yes         | Yes                          | N/A                  | Positive | N/A         | N/A | 59       | 97             | N/A | Yes            | No                        | 10         | No    |
|                    | 55   | F   | N/A         | Yes                          | N/A                  | Positive | N/A         | N/A | 79       | 43             | N/A | Yes            | No                        | 8          | No    |
| Poudy et al^9      | 20   | M   | No          | Yes                          | N/A                  | N/A       | 100         | DQ8 | 86       | N/A             | N/A | No             | Yes                       | N/A         | No    |
| Gutiérrez et al^8   | 26   | F   | Yes         | N/A                          | 3c                   | N/A       | 23.4        | N/A | N/A      | <110           | N/A | No             | Yes                       | N/A         | N/A   |
| Wolf et al^10       | 36   | F   | Yes         | N/A                          | 3c                   | N/A       | N/A         | N/A | <110     | N/A             | N/A | Yes            | No                        | N/A         | No    |
| Forrest et al^11    | 43   | F   | Yes         | Yes                          | 3c                   | N/A       | 608         | N/A | 78       | <100            | 2.1 | Yes            | Yes                       | 107         | No    |
| Akbul et al^12      | 52   | F   | Yes         | N/A                          | Positive             | Positive | N/A         | <100 | N/A      | N/A             | Yes | Yes           | No                        | N/A         | No    |
| Ai Shammeri et al^17| 50   | F   | Yes         | N/A                          | N/A                  | 1/600     | 15          | N/A | N/A      | N/A             | N/A | Yes            | No                        | N/A         | No    |
| Atliou et al^19     | 26   | M   | Yes         | N/A                          | 3                    | Positive | N/A         | N/A | N/A      | N/A             | N/A | No             | Yes                       | N/A         | No    |
| Parry and Acharya^20| 83   | M   | Yes         | N/A                          | Positive             | 6         | N/A         | N/A | N/A      | N/A             | N/A | Yes            | No                        | N/A         | No    |
| Magro and Pullicino^27| 38  | M   | Yes         | Yes                          | 3c                   | N/A       | 35.9        | N/A | 152      | 1.6             | Yes | Yes           | No                        | N/A         | No    |
| Lindo Ricce et al^22| 63   | F   | No          | Yes                          | 3c                   | N/A       | 45          | DQ2 | N/A      | N/A             | Yes | Yes           | No                        | 30          | No    |
| de Almeida Menezes et al^11| 31 | M   | Yes         | No                           | N/A                  | N/A       | N/A         | N/A | N/A      | N/A             | 3.48 | Yes           | No                        | 6           | No    |
| Gonzalez et al^26   | 76   | M   | Yes         | Yes                          | N/A                  | N/A       | N/A         | 102  | N/A      | >10             | N/A | No             | Yes                       | 10          | No    |
| Da Costa Becker et al^27| 49 | F   | Yes         | Yes                          | 3c                   | Positive | Positive | N/A | 72       | 250             | >1.5 | Yes           | Yes                       | N/A         | No    |
| Ferrara et al^29    | 56   | M   | Yes         | Yes                          | N/A                  | N/A       | N/A         | DQ2 | <110     | N/A             | >1.2 | No            | Yes                       | 7           | No    |
| Helvaci et al^29    | 25   | F   | Yes         | Yes                          | 3c                   | N/A       | 100         | N/A | N/A      | N/A             | N/A | Yes           | Yes                       | 14          | No    |
| Chen et al^31       | 24   | F   | Yes         | Yes                          | 3c                   | N/A       | 99          | N/A | 93       | 3.2             | No   | Yes           | No                        | 8           | No    |
| Stai et al^31       | 43   | M   | Yes         | Yes                          | 3c                   | N/A       | 19          | N/A | N/A      | N/A             | N/A | Yes           | No                        | 5           | No    |
| Bul et al^32        | 46   | M   | Yes         | Yes                          | N/A                  | N/A       | 48          | N/A | 110      | N/A             | N/A | No            | Yes                       | N/A         | No    |
| Tiwari et al^33     | 26   | F   | N/A         | Yes                          | N/A                  | N/A       | 100         | N/A | 158      | N/A             | N/A | Yes           | No                        | N/A         | No    |
| Bou-Abboud et al^34 | 69   | M   | Yes         | No                           | 3b                   | N/A       | 132         | N/A | 48       | 1.2             | Yes | No            | Yes                       | N/A         | No    |
| Yilmaz et al^35     | 75   | M   | No          | Yes                          | N/A                  | 3+        | Positive    | N/A | 81       | 180             | N/A | Yes           | Yes                       | 6           | No    |
| Yilmaz et al^35     | 82   | F   | Yes         | N/A                          | 1+                   | Positive  | N/A         | 76  | 156      | N/A             | Yes | Yes           | No                        | 8           | No    |
| Ribeiro da Vale et al^36| 58 | F   | Yes         | Yes                          | 3c                   | 1/640     | 142         | N/A | 116      | 1.6             | No  | Yes           | No                        | 11          | No    |
| Mrad et al^37       | 64   | F   | Yes         | Yes                          | 3c                   | Positive | 200         | N/A | 87       | >1.2            | Yes | Yes           | No                        | N/A         | No    |
|                    |      |     |             |                              |                      |           |             |     |          |                |     |                |                           |            |       |
| **Continued**       |      |     |             |                              |                      |           |             |     |          |                |     |                |                           |            |       |
| Reference        | Age | Sex | Weight loss | Favorable evolution with GFD | Diagnosis | Biopsy (Marsh grade) | TG2 (U/L) | EMA | HLA | Hb (g/L) | PLT (x10^9/L) | INR | Hypoproteinaemia | Electrolyte Abnormalities | LOS (days) | Death |
|------------------|-----|-----|-------------|-------------------------------|-----------|----------------------|-----------|-----|-----|----------|----------------|-----|------------------|-----------------------------|------------|-------|
| Jamma et al(3)   | 34  | F   | Yes         | Yes                           | Favorable evolution with GFD | 3b       | N/A                | 113       | DQ8 | N/A | N/A      | N/A             | N/A | Yes              | N/A                         | 7          | No    |
|                  | 51  | M   | Yes         | Yes                           | Favorable evolution with GFD | 3c       | N/A                | 200       | DQ2 | N/A | N/A      | N/A             | N/A | Yes              | N/A                         | 11         | No    |
|                  | 48  | F   | Yes         | Yes                           | Favorable evolution with GFD | 3b       | N/A                | 0         | DQ2 | N/A | N/A      | N/A             | N/A | Yes              | N/A                         | 4          | No    |
|                  | 70  | M   | Yes         | Yes                           | Favorable evolution with GFD | 3        | N/A                | 100       | N/A | N/A | N/A      | N/A             | N/A | Yes              | N/A                         | 11         | No    |
|                  | 48  | F   | Yes         | N/A                           | Favorable evolution with GFD | 3        | N/A                | 100       | DQ2 | N/A | N/A      | N/A             | N/A | Yes              | N/A                         | 4          | No    |
|                  | 68  | F   | Yes         | Yes                           | Favorable evolution with GFD | 3        | N/A                | 6         | DQ2 | N/A | N/A      | N/A             | N/A | Yes              | N/A                         | 5          | No    |
|                  | 67  | F   | Yes         | Yes                           | Favorable evolution with GFD | 3c       | N/A                | 250       | DQ2 | N/A | N/A      | N/A             | N/A | Yes              | N/A                         | 8          | No    |
|                  | 74  | F   | Yes         | Yes                           | Favorable evolution with GFD | 3c       | N/A                | 24.5      | N/A | N/A | N/A      | N/A             | N/A | No               | N/A                         | 7          | No    |
|                  | 65  | M   | Yes         | Yes                           | Favorable evolution with GFD | 3        | N/A                | 21.3      | DQ2 | N/A | N/A      | N/A             | N/A | Yes              | N/A                         | 10         | No    |
|                  | 68  | M   | Yes         | Yes                           | Favorable evolution with GFD | 3b       | N/A                | 117       | DQ2 | N/A | N/A      | N/A             | N/A | Yes              | N/A                         | 11         | No    |
|                  | 65  | F   | Yes         | Yes                           | Favorable evolution with GFD | 3c       | N/A                | 22        | DQ2 | N/A | N/A      | N/A             | N/A | No               | N/A                         | 13         | No    |
|                  | 49  | F   | Yes         | Yes                           | Favorable evolution with GFD | 3        | N/A                | 83.7      | DQ2 | N/A | N/A      | N/A             | N/A | Yes              | N/A                         | 4          | No    |
| Hammami et al(3) | 26  | F   | Yes         | No                            | Favorable evolution with GFD | N/A      | N/A                | N/A       | N/A | N/A | N/A      | N/A             | N/A | Yes              | N/A                         | 7          | Yes   |
| Toyoshima et al(3) | 30  | F   | Yes         | Yes                           | Favorable evolution with GFD | N/A      | 1/1280             | 5         | N/A | 114 | N/A      | N/A             | N/A | Yes              | Yes                         | N/A         | No    |
| Kelly et al(6)   | 23  | F   | Yes         | Yes                           | Favorable evolution with GFD | N/A      | 33.9               | N/A       | 120 | 94  | N/A      | N/A             | N/A | Yes              | Yes                         | 21         | No    |
| Krishna et al(6) | 67  | M   | Yes         | Yes                           | Favorable evolution with GFD | 3        | Negative           | 4         | DQ8 | 124 | 160      | N/A             | N/A | Yes              | Yes                         | 15         | No    |
| Chandan et al(6) | 58  | M   | Yes         | Yes                           | Favorable evolution with GFD | 3c       | N/A                | 200       | N/A | 47  | N/A      | N/A             | N/A | Yes              | Yes                         | N/A         | No    |
| Kizigil et al(6) | 50  | M   | Yes         | Yes                           | Favorable evolution with GFD | 3        | 158.7              | 200       | N/A | 94  | N/A      | N/A             | N/A | Yes              | N/A                         | No         | No    |
| Selin et al(6)   | 37  | F   | Yes         | Yes                           | Favorable evolution with GFD | 3        | Positive           | Positive  | N/A | 80  | N/A      | N/A             | N/A | Yes              | Yes                         | N/A         | No    |
| Gupta et al(6)   | 30  | F   | Yes         | Yes                           | Favorable evolution with GFD | 3b       | N/A                | N/A       | <110 | N/A | N/A      | N/A             | N/A | Yes              | Yes                         | 7          | No    |
| Present Case     | 34  | F   | Yes         | Yes                           | Favorable evolution with GFD | 3c       | 1/80               | 23        | DQ2 | 85  | 297      | 2.52            | Yes | Yes              | Yes                         | 9          | No    |

EMA, antineumysial antibodies; F, female; GFD, gluten-free diet; Hb, haemoglobin; HLA, human leucocyte antigen; INR, international normalised ratio; LOS, length of stay; M, male; N/A, not applicable; PLT, platelets; TG2, tissue transglutaminase.
ingestion may occur. Only seldom a coeliac crisis can herald the onset of CD, as it was in the herein reported case. Among the reported cases described in table 1, there was a greater prevalence of female than male gender (28 vs 20), with a mean age of 50±17 years, which is higher than the age of the present case. Like in the present case, a higher incidence of coeliac crisis has been reported in patients carrying the HLA-DQ2 haplotype of genetic susceptibility to the disease as compared with those with HLA-DQ8, whereas the biopsy specimens showed signs characteristic of Marsh-Oberhuber 3 (from ‘a’ to ‘c’) mucosal lesions. Other common clinical features included weight loss, hypoproteinaemia and electrolyte abnormalities, whereas coagulation abnormalities (ie, prothrombin time elongation) along with markedly reduced platelet count were uncommon. No clear correlation was found between the anti-TG2 IgA antibody titre and coeliac crisis onset/severity, as also supported by our case showing only a twofold increase above the upper normal limit.

Among the major features of this case were the abrupt onset of symptoms, in particular of those related to electrolyte imbalance, and the severity of the clinical picture prompting admission to the emergency department. Further to severe dehydration, the patient presented with neuromuscular weakness, a finding detected in other reports, and electrocardiographic abnormalities due to the key role exerted by potassium in regulating cell excitability. Likely, hypocalcaemia and hypomagnesaemia also contributed to worsening cellular excitability. According to previous evidence, hypoproteinaemia with hypalbuminaemia and metabolic acidosis were found in our patient as hallmarks of malabsorption, whereas paraesthesia was likely related to electrolyte imbalance. However, the variety of possible clinical pictures in coeliac crisis should be underlined, ranging from central nervous system involvement with tetraplegia/paraplegia and ataxia, as well as seizures, to coagulopathy and acute kidney injury. In all cases described so far, coeliac crisis required urgent hospitalisation. The milestone treatment is fluid resuscitation with correction of the electrolyte imbalance, which can lead to life-threatening cardiac arrhythmias. Nutritional support is also of paramount importance, and clinicians should take coeliac crisis in mind during differential diagnosis of severe acute diarrhoea with weight loss, as patients’ prognosis can dramatically improve with a simple dietary intervention.

In our case, like in almost all cases described, GFD led to a dramatic improvement in clinical picture. Nutritional management should take into consideration the possible occurrence of a refeeding syndrome, which can be fatal if not recognised and treated properly, as described in one patient with coeliac crisis. In less than 20% of cases (8 of 48 cases, 16%), corticosteroids were administered during management. However, we decided not to use steroids since their usefulness was recently questioned. It was reported previously that immunosuppression with corticosteroids and azathioprine for autoimmune hepatitis or prednisone for Bell’s palsy did not prevent the occurrence of coeliac crisis in patients. Moreover, steroid therapy may increase electrolyte depletion, facilitating the occurrence of refeeding syndrome. Finally, despite the acute onset of malabsorption syndrome in adulthood, our case did not show features of complicated CD, (ie, refractory CD), and the clinical picture dramatically improved in a few days with GFD, still the only effective treatment available.

CONCLUSION

The present case highlights the possibility that CD may manifest quite abruptly with a severe malabsorption syndrome and related electrolyte abnormalities and hypoproteinaemia. This would imply that even a typically chronic disorder, such as CD, may have an acute onset in a small proportion of patients, which emergency physicians should be aware of. Although rarely encountered in clinical practice, this acute onset of CD requires hospitalisation and immediate treatment (ie, electrolyte replacement and protein correction) in order to avoid life-threatening complications.

Contributors MG, RDG and GC: design and conceptualisation. MG, EG and FA reviewed the literature and wrote the first draft of the manuscript. AS, RC, LL, GZ, UV, RDG and GC participated in the clinical assessment of the patient and critically reviewed the paper.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data sharing not applicable as no data sets generated and/or analysed for this study.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Rachele Cicocioppo http://orcid.org/0000-0002-6297-7576
Giacomo Caio http://orcid.org/0000-0002-4244-4529

REFERENCES

1. Caio G, Volta U, Sapone A, et al. Celiac disease: a comprehensive current review. BMC Med 2019;17:142.
2. Valtutti F, Fasano A. Breaking down barriers: how understanding celiac disease pathogenesis informed the development of novel treatments. Dig Dis Sci 2019;64:1748–58.
3. Trovato CM, Raucci U, Valtutti F, et al. Neuropsychiatric manifestations in celiac disease. Epilepsy Behav 2019;99:106393.
4. Volta U, Caio G, Stanghellini V, et al. The changing clinical profile of celiac disease: a 15-year experience (1998-2012) in an Italian referral center. BMC Gastroenterol 2014;14:194.
5. Caio G, Volta U. Coeliac disease: changing diagnostic criteria? Gastroenterol Hepatol Bed Bench 2012;5:119–22.
6. Waheed N, Cheema HA, Suleman H, et al. Celiac crisis: a rare or rarely recognized disease. J Ayub Med Coll Abbottabad 2016;28:672–5.
31. Stai B, Bourgain G, Luciano L, et al. Celiac crisis in a multi-trauma adult patient. Clin Res Hepatol Gastroenterol 2016;40:e31–2.
32. Bul V, Slesesan B, Boulay B. Celiac Disease Presenting as Profound Diarrhea and Weight Loss - A Celiac Crisis. Am J Case Rep 2016;17:559–61.
33. Twari A, Qamar K, Sharma H, et al. Urinary tract infection associated with a celiac crisis: a preceding or precipitating event? Case Rep Gastroenterol 2017;11:364–8.
34. Bou-Abboud C, Katz J, Liu W. Firing of an implantable cardiac defibrillator: an unusual presentation of celiac crisis. ACG Case Rep J 2018;6:e137.
35. Yilmaz A, Aksoy EK, Kahraman R, et al. Atypical presentation of celiac disease in an elderly adult: celiac crisis. J Am Geriatr Soc 2015;63:1712–4.
36. Ribeiro do Valle R, da Silva Conci N, Santana AP, et al. La Laborda and Felipe da Silva as, celiac crisis: an unusual presentation of gluten-sensitive enteropathy. Autopsy Case Report 2018;8:e20180207.
37. Mrad RA, Ghaddara HA, Green PH, et al. Celiac crisis in a 64-year-old woman: an unusual cause of severe diarrhea, acidosis, and malabsorption. ACG Case Reports Journal 2015;2:95–7.
38. Jamma S, Rubio-Tapia A, Kelly CP, et al. Celiac crisis is a rare but serious complication of celiac disease in adults. Clin Gastroenterol Hepatol 2010;8:587–90.
39. Hamamni S, Aref HL, Khalfa M, et al. Refeeding syndrome in adults with celiac crisis: a case report. J Med Case Rep 2018;12:22.
40. Toyoshima MTK, Queiroz MS, Silva MER, et al. Celiac crisis in an adult type 1 diabetes mellitus patient: a rare manifestation of celiac disease. Arq Bras Endocrinol Metab 2013;57:650–2.
41. Kelly E, Cullen G, Aftab AR, et al. Coeliac crisis presenting with cytomegalovirus hepatitis. Eur J Gastroenterol Hepatol 2006;18:793–5.
42. Krishna K, Krishna SG, Covioello-malle JM, et al. Celiac crisis in a patient with chronic lymphocytic leukemia and hypogammaglobulinemia. Clin Res Hepatol Gastroenterol 2011;35:70–3.
43. Chandan S, Ahmad D, Hewlett A. Celiac crisis: a rare presentation of celiac disease in adults. 2016.. ACG 2016 conference paper.
44. Kizilgil M, Kan S, Celik S, et al. Celiac crisis in an adult type 1 diabetes mellitus patient presented with diarrhea, weight loss and hypoglycemic attacks. Int J Diabetes Dev Ctries 2014;21:60–2.
45. Gupta T, Mandal A, Desai D, et al. Celiac crisis with hypogamaglobulinemia. Can J Gastroenterol 2010;37:85–7.
46. Volta U, Fabbri A, Paroli U, et al. Old and new serological tests for celiac disease screening. Expert Rev Gastroenterol Hepatol 2010;4:31–5.
47. Amnani S, Alvisi P, De Giorgio R, et al. Antibodies to deaminated gliadin peptides: an accurate predictor of coeliac disease in infancy. J Clin Immunol 2013;33:1027–30.
48. Balaban DV, Dima A, Jurtçuc G, et al. Celiac crisis, a rare occurrence in adult celiac disease: a systematic review. WJJC 2019;7:311–9.
49. Gupta S, Kapoor K. Steroids in celiac crisis: doubtful role! Indian Pediatr 2014;51:756–7.
50. Volta U, Caio G, Tovoli F, et al. Gut-liver axis: an immune link between celiac disease and primary biliary cirrhosis. Expert Rev Gastroenterol Hepatol 2013;7:253–61.
51. Caio G, Volta U, Ursini F, et al. Small bowel adenocarcinoma as a complication of celiac disease: clinical and diagnostic features. BMC Gastroenterol 2019;19:45.
52. Vanoli A, Di Sabatino A, Furlan D, et al. Small Bowel Carcinomas in Coeliac or Crohn’s Disease: Clinico-pathological, Molecular, and Prognostic Features. A Study From the Small Bowel Cancer Italian Consortium. J Crohns Colitis 2017;11:942–53.